Table of Contents The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a Below is the key information for Nippon India Pharma Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis Nippon India PHARMA Fund - G
Scheme Objective
CAGR
return of 20.3% since its launch. Ranked 35 in Sectoral
category. Return for 2022 was -9.9% , 2021 was 23.9% and 2020 was 66.4% . NAV as on 22 Aug 23 ₹349.301 ↑ 0.24 (0.07 %) Net Assets (AUM) as on 31 Jul 2023 ₹5,392 Cr. Launch Date 5 Jun 2004 Category Equity - Sectoral Rating ☆☆ Type Open Ended Fund Risk High AMC Nippon Life Asset Management Ltd. Alpha Ratio 2.26 Expense Ratio 1.97 % Sharpe Ratio 1.198 Information Ratio 0.62 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹100 Exit Load 0-1 Years (1%),1 Years and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis
& more than 1 year are on CAGR (Compound Annual Growth Rate)
basis. as on 22 Aug 23 Duration Returns 1 Month 5.6% 3 Month 24.7% 6 Month 29.2% 1 Year 27.3% 3 Year 16.2% 5 Year 17.5% 10 Year 15 Year Since launch 20.3% Historical Annual Returns
Year Returns 2022 -9.9% 2021 23.9% 2020 66.4% 2019 1.7% 2018 3.6% 2017 7.6% 2016 -10.6% 2015 19.4% 2014 49.5% Growth of 10k Over Years
Date Value 31 Aug 18 ₹10,000 31 Aug 19 ₹8,733 31 Aug 20 ₹13,180 31 Aug 21 ₹19,501 31 Aug 22 ₹17,099 31 Aug 23 ₹21,433 Asset Allocation
Asset Class Value Cash 3.22% Equity 96.78% Sector Allocation
Sector Value Health Care 96.78% Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMADrug Manufacturers - Specialty & Generic 13% ₹729 Cr 6,556,349 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 500257Drug Manufacturers - Specialty & Generic 8% ₹418 Cr 3,803,676
↓ -200,000 Cipla Ltd Shs Dematerialised (Healthcare)
Equity, Since 31 May 08 | 500087Drug Manufacturers - General 7% ₹377 Cr 3,000,000 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDYDrug Manufacturers - Specialty & Generic 6% ₹308 Cr 550,030 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLANDDrug Manufacturers - General 5% ₹261 Cr 1,500,000
↑ 300,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLABDrug Manufacturers - Specialty & Generic 5% ₹252 Cr 700,808 Medplus Health Services Ltd (Healthcare)
Equity, Since 30 Nov 22 | 543427Pharmaceutical Retailers 5% ₹250 Cr 3,076,603
↑ 1,160,000 Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Dec 15 | AUROPHARMADrug Manufacturers - Specialty & Generic 4% ₹208 Cr 2,500,000
↓ -500,000 J.B. Chemicals & Pharmaceuticals Ltd Shs Dematerialised (Healthcare)
Equity, Since 31 Jan 22 | JBCHEPHARMDrug Manufacturers - Specialty & Generic 4% ₹207 Cr 748,446
↓ -10,132 Zydus Lifesciences Ltd (Healthcare)
Equity, Since 31 Jan 18 | 532321Drug Manufacturers - Specialty & Generic 4% ₹200 Cr 3,200,835
Talk to our investment specialistFund Managers
Name Since Tenure Sailesh Raj Bhan 1 Apr 05 18.43 Yr. Kinjal Desai 25 May 18 5.27 Yr. Akshay Sharma 1 Dec 22 0.75 Yr. Custodians
Company Address Deutsche Bank AG Deutsche Bank AG,Kodak House, 22, D.N. Road, Registrar & Transfer Agent
KFin Technologies Ltd Address KFin Technologies Pvt. Ltd,,1D/D Extension 2, Valmiki Chowk,,Gandhi Nagar, FAX 91-40-23311968 Email mailmanager@karvy.com Administrator Companies
Company Address Nippon India Mutual Fund 9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051 Auditors
Company Address Haribhakti & Co. Chartered Accountants 42, Free Press House,4th Floor,,215, Nariman Point, All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year Nippon India Pharma Fund
Normal Dividend, Payout ₹96.9949
↑ 0.07 29.22 % 27.26 % 20.83 % 19.83 % Nippon India Pharma Fund
Normal Dividend, Reinvestment ₹96.9949
↑ 0.07 29.22 % 27.26 % 20.83 % 19.83 % Nippon India Pharma Fund
Growth ₹349.301
↑ 0.24 29.22 % 27.26 % 16.16 % 17.49 % Data as on 22 Aug 23